How long can you live taking Ruxolitinib?

Ruxolitinib is the only JAK inhibitor approved for the treatment of myelofibrosis (MF) patients. The drug mainly inhibits dysregulated JAK-STAT signaling, which is present in all MF patients regardless of their JAK2 mutation status. However, it is not selective for mutated JAK2 and is very effective in shrinking the spleen and controlling MF symptoms, thereby significantly improving the patient's quality of life.

The therapeutic effect of ruxolitinib tablets is usually significant, but it is also drug-dependent, because spleen enlargement and symptom recurrence occur rapidly after drug withdrawal or dose reduction. There was also no clear indication of disease-modifying effect, and most patients discontinued treatment due to adverse events or lack of efficacy. About 50% of patients stop ruxolitinib tablets within 3 years of treatment. Salvage treatment options are still scarce, and most include allogeneic stem cell transplantation (allo-SCT) and immunomodulators; however, the prognosis is poor.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. Specification The price of each box of 5mg*60 tablets may be around RMB 3,000. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.